World Journal of Clinical Cases - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6780)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

193

WORD

HTML

3875

Figures (1-4)

610

Tables (1-1)

568

Sum=5273

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

205

Download

1072

Sum=1277

Jan 6, 2024 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases 2024; 12(1): 32-41 [PMID: 38292624 DOI: 10.12998/wjcc.v12.i1.32]
URL:	https://www.wjgnet.com/2307-8960/full/v12/i1/32.htm

Number	Citing Articles
1	Anna‐Lena Lemster, Sarah Grünhagen, Sarah Schmalfeld, Florian Lenz, Anna Natzius, Anne Offermann, Sven Perner, Jiong Zhang, Verena Sailer, Jutta Kirfel. Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer. The Prostate 2025; 85(12): 1121 doi: 10.1002/pros.24925
2	Zhi-Yu Zhang, Jun Ouyang, Jiang-Lei Zhang, Qi Zhou, Zhen Song. Correction to: Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World Journal of Clinical Cases 2024; 12(36): 6950-6951 doi: 10.12998/wjcc.v12.i36.6950 Abstract(503) \| Core Tip(510) \| Full Article(HTML)(1438) \| Full Article with Cover (PDF)-553K(101) \| Audio-121K(14) \| Answering Reviewers-57K(93) \| Full Article (PDF)-303K(118) \| Full Article (XML)-9K(85) \| Times Cited (0) \| Total Visits (3860) \| Open
3	Shristi Modanwal, Viswajit Mulpuru, Ashutosh Mishra, Nidhi Mishra. Transcriptomic signatures of prostate cancer progression: a comprehensive RNA-seq study. 3 Biotech 2025; 15(5) doi: 10.1007/s13205-025-04297-3
4	Liu Xiao, Yuhao Li, Yikai Xing, Lin Li. Value of integrated PET-IVIM MRI in predicting Ki-67 expression in newly diagnosed prostate cancer. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-02467-0
5	Qingchang Ren, Jialong Gu, Nankang Lu. Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression. Open Life Sciences 2026; 21(1) doi: 10.1515/biol-2025-1244
6	Al-Hassan T. Waly, Abed H. Baraaj. <b>The Indispensable Role of Immunohistochemistry in Differentiating Prostate Cancer from Benign Prostatic Hyperplasia</b>. Journal of the Faculty of Medicine Baghdad 2025; 67(4): 464 doi: 10.32007/jfacmedbaghdad3185
7	Li Yan, Pengxiao Su, Xiaoke Sun. Role of multi‑omics in advancing the understanding and treatment of prostate cancer (Review). Molecular Medicine Reports 2025; 31(5): 1 doi: 10.3892/mmr.2025.13495
8	Desheng Zhu, Shiyong Huang. Construction and validation of a lysine beta hydroxybutyrylation related molecular model for predicting biochemical recurrence of prostate cancer. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-12314-x